CLYM116 shows deep, durable APRIL suppression; 12-week dosing supported
CLYM116, an anti-APRIL antibody for IgA nephropathy, showed deep and durable APRIL suppression and favorable safety in phase I, with reductions in IgA, Gd-IgA1 and IgM. PK/PD supports 12-week dosing; phase II and III planned.
CLYM116, a next-generation anti-APRIL antibody for IgA nephropathy, demonstrated deep and durable APRIL suppression, favorable safety, and robust reductions in IgA, Gd-IgA1, and IgM in phase I.
The PK/PD profile supports a 12-week dosing regimen, with phase II and III studies planned.Based on Climb…